Article Figures & Data
Figures
- Figure 1.
Detection of ERG and PTEN status by IHC and FISH. An ERG+/PTENdel biopsy is represented. A, H&E of needle biopsy showing prostatic adenocarcinoma, Gleason score 7. B, strong, diffuse nuclear ERG IHC staining of tumor glands. ERG break-apart FISH assay showing ERG translocation (inset). C, absence of PTEN IHC staining in tumor glands. FISH assay showing hemizygous PTEN loss (inset).
- Figure 2.
Prostate cancer relapse-free survival according to PTEN and ERG IHC status. Kaplan–Meier curves are reported with respect to recurrence-free survival for PTEN loss identified by IHC (A), for ERG+ prostate cancer identified by IHC (B), and for their combination (C).
Tables
- Table 1.
Study cohort demographics
Number of patients 92 Age (y) (mean ± SD) 65.8 ± 5 cT, N (%) cT1 50 (54) cT2/3 42 (46) PSAi (ng/mL), N (%) <4 7 (8) 4 ≤ x< 10 59 (64) >10 26 (28) Risk group, N (%) L 55 (60) I 32 (35) H 5 (5) Gleason score, N (%) 6 68 (74) 7 16 (17) 8 8 (9) International prostate symptom score, N (%) <8 80 (87) ≥ 8 12 (13) Volume transrectal ultrasound (cc) (mean ± SD) 34 ± 9 BCR, N (%) No event 82 (89) Event 10 (11) RFS (mo) (mean ± SD) No event 72 ± 28 Event 50 ± 33 OS (mo) (mean ± SD) (median) No event 72 ± 28 (70) Event 90 ± 30 (96) Hormonal therapy pre-implant No 58 (63) Yes 34 (37) - Table 2.
Association of ERG and PTEN IHC status with clinicopathologic features
ERG IHC PTEN IHC ERG/PTEN IHC Neg Pos P-value Neg Pos P-value Neg/no loss Pos/no loss Neg/loss Pos/loss P-value Age ≤ Median 23 26 0.58 35 13 0.94 20 15 3 10 0.86 > Median 16 23 28 10 13 15 2 8 PSAi (ng/mL) < 4 3 4 0.97 4 2 0.93 1 3 1 1 0.46 4 ≤ x < 10 24 31 40 14 20 20 4 10 > 10 12 14 19 7 12 7 0 7 cT 1 24 22 0.21 35 10 0.32 19 16 4 6 0.21 2/3 15 27 28 13 14 14 1 12 Risk group H 3 2 0.62 2 3 0.18 2 0 1 2 0.44 I 12 19 22 9 11 11 1 8 L 24 28 39 11 20 19 3 8 Gleason score 6 29 36 0.68 49 14 0.13 26 23 2 12 0.18 7 6 10 11 5 5 6 1 4 8 4 3 3 4 2 1 2 2
April 2014
Volume 23, Issue 4
Volume 23, Issue 4
Recurrent Prostate Cancer Genomic Alterations Predict Response to Brachytherapy Treatment
Jump to section
Advertisement